EFFECTIVENESS AND SAFETY MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS

Archilla Amat MI, Montero-Vilchez C, Cantudo Cuenca MR Farmacia. Hospital Virgen de las Nieves, Granada



Background and Importance


Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP-mAbs) are used in the prophylaxis of migraine. The therapeutic target is not exactly the same as Erenumab targets the CGRP receptor, whereas Galcanezumab and Fremanezumab target circulating CGRP. However, their relative effects in patients with prior migraine treatment failure remains uncertain.

Aim and Obietives

To describe the use, effectiveness and safety of CGRP-mAbs switching in patients with migraine

Material and Methods

- ✓ Retrospective observational study: 1 September 2019 30 September 2022
- ✓ Data collected: sex, age, comorbidities, CGRP-mAbs prescribed, treatment duration, causes of suspensión, adverse reactions, Headache Impact Test (HIT) and Migraine Disability Assessment (MIDAS) scores, average number of migraine days per month (NMDM) and days with triptans at baseline, prior and concomitant preventive drugs.
- ✓ Data were obtained from electronic medical records and patients interviews.
- ✓ The study had been approved by the Ethics Committee. Informed consent was obtained from all participants.



Conclusion and Relevance

Some migraine patients who did not respond to a first drug responded to the switch, however half of them need to switch to a third mAb. Treatment with mAbs can be considered safe.



